文献类型：期刊文献

中文题名：黄芪总苷对脊髓型颈椎病大鼠模型椎间盘细胞因子IL-6、TNF-α的影响

英文题名：The Effects of Astragalosides on Cell Factors IL-6 and TNF-αof Intervertebral Disc of the Rats with Cervical Spondylotic Myelopathy

作者：丁海霞[1];樊成虎[2];王玉泉[2];兰晓飞[3]

第一作者：丁海霞

机构：[1]甘肃中医药大学附属医院,甘肃兰州730000;[2]甘肃省中医院;[3]甘肃中医药大学

第一机构：甘肃中医药大学第二附属医院

年份：2017

卷号：30

期号：7

起止页码：20

中文期刊名：西部中医药

外文期刊名：Western Journal of Traditional Chinese Medicine

收录：CSTPCD

语种：中文

中文关键词：脊髓型颈椎病;IL-6;TNF-α;黄芪总苷

外文关键词：cervical sondylotic melopathy; IL-6; TNF-α; atragalosides

摘要：目的:观察黄芪总苷对脊髓型颈椎病(CSM)模型大鼠椎间盘中细胞因子白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)含量及脊髓形态变化的影响,探讨黄芪总苷在治疗脊髓型颈椎病中的可能机制。方法:110只大鼠除去空白对照组18只外,其余大鼠在颈椎间盘后缘植入BMP复合剂制作CSM大鼠模型后随机分为5组,即模型组,黄芪总苷高、中、低剂量组和甲钴胺药物组,根据实验设计分别做相应的灌胃处理,严格无菌条件取材后HE染色观察脊髓形态学变化,检测椎间盘中IL-6、TNF-α的含量。结果:模型组及黄芪总苷高、中、低剂量组和甲钴胺药物组内IL-6、TNF-α的含量高于空白对照组(P<0.05);黄芪总苷高、中、低剂量组和甲钴胺药物组内IL-6、TNF-α的含量均低于模型组(P<0.05);黄芪总苷中剂量组内IL-6、TNF-α的含量低于黄芪总苷高、低剂量组,用药1周后与甲钴胺药物组比较无差异,用药4周后较甲钴胺药物组低(P<0.05)。组织HE切片显示空白对照组、模型组及黄芪总苷高、中、低剂量组比较有差异,黄芪总苷中剂量组和甲钴胺药物组比较有差异。结论:黄芪总苷显著降低了颈椎间盘中细胞因子IL-6、TNF-α的含量,且存在量效差异;黄芪总苷通过降低颈椎间盘中细胞因子的含量,减缓或改善椎间盘的退变,对CSM起预防和治疗作用。
Objective： To discuss the possible mechanism of atragalosides in treating cervical sondylotic melopathy（CSM） by observing its effects on the contents of IL-6 and TNF-α in intervertebral disc and morphological changes of spinal cord of CSM rats. Methods： Among 110 rats, 18 rats were taken as blank control group, and the rest of the rats accepted the implanting of BMP complexing agent at posterior margin of cervical intervertebral disc to prepare the rat model, they were randomly allocated to five groups： the model group, high, moderate and low dosages groups of atragalosides, and mecobalamine group, and the rats accepted corresponding intragastric administration according to experimental design, morphological changes of spinal cord were observed by HE staining after the tissue was taken under strict aseptic conditions, and the contents of IL-6 and TNF-c~ in intervertebral disc were detected. Results： The contents of IL-6 and TNF-a in the model group, high, moderate and low dosages groups of atragalosides, and mecobalamine group were higher than these of blank control group （P〈0.05）; high, moderate and low dosages groups ofatragalosides, and mecobalamine group were lower than these of the model group in the contents of IL-6 and TNF-α （P〈0.05）; in the contents oflL-6 and TNF-α in moderate dosages group of atragalosides were lower than these of high and low dosages groups of atragalosides notably, there was no difference compared with mecobalamine group after medieation for one week, they were lower compared with mecobalamine group after medication for four weeks （P〈0.05）, and tissue HE staining slices demonstrated that there were differences when blank control group and the model group were compared with high, moderate and low dosages groups of atragalosides, there was difference when moderate dosages group ofatragalosides was compared with mecobalamine group. Conclusion： Atragalosides could notably decrease the contents of IL-6 and TNF-α in intervertebral disc, and there is dose-effect difference. It could prevent and treat CSM by lowering the contents of cell factors in intervertebral disc, relieving and improving degeneration of intervertebral disc.